Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6137 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Bing Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Antitubercular Agents, 5-Aminolevulinate Synthetase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The accumulation of protoporphyrin IX in the liver caused by isoniazid and rifampicin through the disorder of heme biosynthesis was considered an important mechanism of anti‐tuberculosis drug‐induced liver injury (ATLI). Alanine synthase 1 (ALAS1) is a rate‐limiting enzyme in the process of heme synthesis. This study aimed to investigate the association between ALAS1 gene polymorphism, serum ALAS1 level, and the risk of ATLI. This study was a case‐control study including 58 ATLI cases and 192 controls. Four single nucleotide polymorphisms (SNPs) of the ALAS1 gene were selected for genotyping and serum ALAS1 concentrations were detected using ELISA kits. There was no significant difference in the genotype distribution of four SNPs between the ATLI cases and the controls under different genetic models. Patients carrying the GG genotype of SNP rs352163 in controls had higher baseline ALAS1 levels than those in ATLI cases (243.6 vs 290.2 ng/L, P = .034), and patients with baseline ALAS1 < 337.85 ng/L had a higher risk of ATLI than those with ALAS1 ≥ 337.85 ng/L (HR = 2.679, 95% CI: 1.360‐5.278, P = .004). Our findings indicated that the serum ALAS1 concentrations in the ATLI cases were lower than those in the controls, and the lower baseline ALAS1 levels can be associated with higher ATLI risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
- Department of Infectious Disease, The Jurong Hospital Affiliated to Jiangsu University, Jurong, China.
- Department of Tuberculosis, The Second People's Hospital of Changshu, Changshu, China.
- Department of Tuberculosis, Changshu Center for Disease Control and Prevention, Suzhou, China.
- Department of Infectious Disease, The People's Hospital of Taixing, Taixing, China.
ORCID-Profile: Shaowen Tang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, B., He, Y., Zhu, M., Zhang, M., Lu, L., Xu, X., He, X., Yi, H., & Tang, S. (2025). Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6137
Vancouver
Han B, He Y, Zhu M, Zhang M, Lu L, Xu X, et al. Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6137
BibTeX
@article{Han2025,
author = {Han, Bing and He, Yiwen and Zhu, Min and Zhang, Meiling and Lu, Lihuan and Xu, Xiaoyan and He, Xiaomin and Yi, Honggang and Tang, Shaowen},
title = {Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6137}
}
EUVIMED